Trinity Biotech plc (TRIB) Stock Score, Valuation & Financial Research
Trinity Biotech plc is in the Healthcare sector and Medical - Specialties industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 10/100.
Quick answer for TRIB
Trinity Biotech plc currently has a Wall Street Score of 10/100. The stored market price is $7.74. Its financial score is 3/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Trinity Biotech plc does
Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases. These include Lyme disease, sexually transmitted infections like syphilis and herpes, SARS-CoV-2, and a variety of viral pathogens such as Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. Additionally, Trinity Biotech provides in-vitro diagnostic products centered on haemoglobin A1c for the crucial monitoring, diagnosis, and risk assessment of diabetes. T
TRIB financial snapshot
- Wall Street Score:
- 10/100
- Current price:
- $7.74
- Market capitalization:
- $156.7M
- Revenue:
- $43.9M
- Net income:
- $-37.4M
- Free cash flow:
- $-12.2M
- Cash:
- $5.1M
- Total debt:
- $138.0M
- EPS:
- -2.00
- Financial score:
- 3/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-12.2M, showing cash burn in the current stored period.
- The balance sheet shows $5.1M of cash versus $138.0M of total debt, so leverage deserves attention.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 3/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research TRIB
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.